Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-074-2 | CAS number: 25524-95-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The acute median lethal dose (LD50) in rats following single oral administration of Jasminlactone was greater than 4000 mg/kg in female or male rats.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 09 June 1992 - 23 June 1992
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Principles of method if other than guideline:
- Ministry of Health and Welfare's "Regarding standards for conducting a safety study of medicine" (PAB Notification No.313, March 31, 1982),
"Regarding partial revision of standards for conducting a safety study of medicine" (PAB Notification No.776, October 1, 1983),
"Regarding revision of regulations about GLP and inspection for medicine" (PAB Notification No.870, October 5, 1988), and
"Regarding guidelines on a toxicity study for an application of manufacturing (import) - GLP compliance:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: Lot No.19001
- Purity: 95.0 %
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Cool and dark place after replacement by N2
- Stability under test conditions: It is stable under test conditions.
- Solubility and stability of the test substance in the solvent/vehicle: It can dissolve in alcohol and resolve in water, alkali and alcohol - Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 4 weeks
- Fasting period before study: 18 hours
- Weight at study initiation: The male and female rats weighed 136 to 144 g and 110 to 119 g, respectively
- Housing: The animals were housed in room 5 of flat A (SPF facility), and each rat was in one stainless bracket cage for rats, SN-790-2 (260W x 380D x 180H mm).
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 10 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 to 24
- Humidity (%): 46 to 65
- Air changes (per hr): 12
- Photoperiod (hrs dark / hrs light): 12 hours - Route of administration:
- oral: gavage
- Vehicle:
- not specified
- Doses:
- Preliminary test: 250, 500, 1000, 2000, and 4000 mg/kg
Definitive test: 0 mg/kg, 2000 mg/kg and 4000 mg/kg - No. of animals per sex per dose:
- 5
- Control animals:
- yes
- Details on study design:
- General state of health.
We observed and checked any change in the general state of health and the number of death cases at 5, 15, and 30 minutes, and 1, 3, 6, and 24 hours after the administration and then twice daily until the 14th day.
Body weight
We measured body weight on the 0, 1, 2, 3, 7, 10, and 14 days after the administration.
Anatomical dissection
After the observation period was over, all the cases were bled to death under ether anesthesia, and we observed the body surface, inside the skull, thoracic cavity, and abdominal cavity with the naked eye.
Histopathological test
We did not conduct a histopathological test because no abnormal change was observed in the anatomical dissection. - Statistics:
- Method for statistical analysis:
Concerning change in body weight, first we obtained an average value and standard deviation in each group. Then, if uniformity of dispersion was observed with F-test, we conducted the Student's t-test, otherwise we conducted Aspin-Welch's t-test, in order to compare the treatment groups to the control. - Preliminary study:
- In the preliminary test conducted a dose of 250, 500, 1000, 2000, and 4000 mg/kg of the substance were administered to five groups respectively, each of which consisted of 2 male and 2 female animals. No death resulting from test item was observed. Therefore, the maximum doses of 2000 mg/kg and 4000 mg/kg) were chosen in the main study.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 4 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- One case of death was observed in the females assigned to the 4000 mg/kg group 3 hours after the administration.
- Clinical signs:
- other: 4000 mg/kg group: Salivation was observed in 2 or 3 females 5 minutes to 1 hour after the administration; salivation was observed in 2 male rats 3 hours after the administration. In addition, decreased activity was observed in 1 or 2 female and male rats
- Gross pathology:
- A noteworthy change was not observed in the fatal case of the female rat in the 4000 mg/kg group and in any surviving male or female rats in all groups.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- One death was observed in the 5 females in the 4000 mg/kg group while no case of death was observed in the males. No difference was observed in both general state of health and change in body weight between the females and the males. Therefore, LD50 of test item in this study was estimated to be greater than 4000 mg/kg in both female and male rats.
- Executive summary:
A study was performed to assess the acute oral toxicity of the test item to Crj:CD(SD) rats. A single dose of test item at 0, 2000 and 4000 mg/kg were administered orally to three groups of Crj:CD(SD) rats, each of which consisted of 5 females or 5 males. After the administration, the rats were observed for 14 days for examination of signs of toxicity.
One death was observed in the 5 females in the 4000 mg/kg group. Transient salivation and decreased activity were observed in a few females and males in both groups in 5 minutes to 3 hours after administration. Significant restraint on increase of body weight was observed on the 1st day in both the females and the males in 4000 mg/kg group, however the condition started making a recovery on the 2nd day or later, and reached approximately same levels as the control group on the 7th day or later. At autopsy, no abnormal change was observed in any females and males in each group including the fatal case.
One death was observed in the 5 females in the 4000 mg/kg group. No difference was observed in both general state of health and change in body weight between the females and the males. Therefore, LD50 of test item in this study was estimated to be about 4000 mg/kg in both female and male rats
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- > 4 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
An acute oral toxicity study was conducted (Nippon Experimental Medical Research Institute, 1992, Study H-92032) to assess the toxicity of Jasminlactone following a single oral administration. The study was conducted in accordance with the Ministry of Health and Welfare's "Regarding standards for conducting a safety study of medicine" (PAB Notification No.313, March 31, 1982), "Regarding partial revision of standards for conducting a safety study of medicine" (PAB Notification No.776, October 1, 1983), "Regarding revision of regulations about GLP and inspection for medicine" (PAB Notification No.870, October 5, 1988), and "Regarding guidelines on a toxicity study for an application of manufacturing (import) approval for medicine" (PAB/ED Notification No.1-24, September 11, 1989) and in compliance with GLP.
In the preliminary test single doses of 250, 500, 1000, 2000, and 4000 mg/kg of Jasminlactone were administered via oral gavage to five groups each consisting of 2 male and 2 female Crj:CD(SD) rats. As no deaths were observed, the main test was carried out with the maximum doses from the preliminary test. A single dose of 0, 2000, 4000 mg/kg of Jasminlactone were administered to three groups each consisting of 5 female or 5 male rats. The animals were observed for 14 days.
One female rat assigned to the 4000 mg/kg group has died. Salivation and decreased activity were observed in male and female rats in both dose groups; however, these disappeared 3 - 6 hours after the administration. Therefore, they were considered to be a reflection of pharmacologic effect of Jasminlactone. In addition, loose stool, recumbent state, and lowered body temperature were observed in the case of dead animal. Significant restraint on increase of weight was observed on the 1st day after the administration in both the females and the males assigned to the 4000 mg/kg group, compared to the control group, however the animals started making a recovery on the 2nd day or later, and weights have reached the approximately same level as the control group on the 7th day or later. No changes resulting from the Jasminlactone were observed in anatomical dissection of any females and males in each group.
It was concluded that the acute median lethal dose in rats following single oral administration of Jasminlactone was greater than 4000 mg/kg in female or male rats.
No acute inhalation toxicity or acute dermal study was conducted.
Justification for classification or non-classification
The acute oral LD50 of Jasminlactone was determined to be greater than 4000 mg/kg. According to table 3.1.1 of CLP Regulation (Commission Regulation 1272/2008) Jasminlactone is not classified for acute oral toxicity.
No test data is available classify Jasminlactone for acute dermal or inhaled toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.